Macquarie Group’s Lyell Immunopharma LYEL Stock Holding History

Macquarie Group’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25	Closed	-$732	–	1814
2024 Q2	$732	Buy	+25	New	+$1.19K	﹤0.01%	1861

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's LYEL Position: Q3 2024 in Review

Macquarie Group sold out of Lyell Immunopharma (LYEL) in Q3 2024, closing a stake of 25 shares — an estimated $732 sold.

Macquarie Group first reported a position in LYEL in Q2 2024 and held it in 1 quarter. The position peaked at $732 in Q2 2024. 117 funds tracked by Wall St. Rank hold LYEL as of Q3 2024.

Macquarie Group reported no remaining Lyell Immunopharma position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 25 Lyell Immunopharma shares in Q3 2024, an estimated $732.
Macquarie Group first reported a position in Lyell Immunopharma in Q2 2024 and held it in 1 quarter.
Macquarie Group's Lyell Immunopharma position peaked at $732 in Q2 2024.
117 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.